Pembrolizumab in Combination With CRT for LA-SCCHN

NCT02586207 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Squamous Cell Carcinoma
Oral Cavity Cancer
Oropharynx Cancer
Hypopharynx Cancer
Larynx Cancer
Laryngeal Cancer

Interventions

DRUG: pembrolizumab (MK-3475)
DRUG: Cisplatin
RADIATION: Radiation

Sponsor

Sanford Health

Collaborators

[object Object]